Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy.

Recombinant adeno-associated viral (rAAV) vector-mediated gene therapy is being developed to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. In preparation for a clinical gene therapy trial, we conducted dose range-finding (DRF) studies with an AAV2 capsid with three surface tyrosine residues changed to phenylalanine (AAV2tYF) vector administered by subretinal injection in a naturally occurring RPGR-mutant canine model (XLPRA2) to compare two different human RPGR (hRPGR) transgenes and to establish a reasonable starting dose for a clinical trial. Different dose levels of two candidate vectors (0.15 mL at 1.2 x 1010 - 3.0 x 1012 vg/mL of rAAV2tYF-GRK1-hRPGRco or 4 x 1010 - 3.0 x 1012 vg/mL of rAAV2tYF-GRK1-hRPGRstb), 6.0 x 1011 vg/mL rAAV5-GRK1-hRPGRco reference vector or Vehicle were subretinally administered and the dogs were followed for 8 weeks post dose. Ophthalmic exams, analyses of retinal structure by in vivo imaging using confocal scanning laser ophthalmoscopy (cSLO)/optical coherence tomography (OCT) in the Lower (4.0 x 1010 vg/mL) and Lowest (1.2 x 1010 vg/mL) Doses, immunological responses by cell based assays or ELISA, RPGR transgene expression, and reversal of opsin mislocalization by immunohistochemistry (IHC) were performed. No sustained signs of ocular discomfort or ophthalmic complications were noted in any of the injected eyes except some in the High Dose group (3.0 x 1012 vg/mL), which showed signs of retinal detachment and inflammation. A change in fundus reflectivity suggestive of a rescue effect was seen in the High, Mid (6.0 x 1011 vg/mL), and Low (1.2 x 1011 vg/mL) Dose groups. cSLO/OCT demonstrated qualitative and quantitative evidence of rescue effect in eyes treated with the Lower Dose. Anti-hRPGR antibodies were absent but NAb titers against AAV2 were detected in all animals dosed with rAAV2tYF in an apparent dose-related pattern. RPGR expression was stronger for rAAV2tYF-GRK1-hRPGRco compared to rAAV2tYF-GRK1-hRPGRstb at all dose levels. Subretinal administration of rAAV2tYF-GRK1-hRPGRco and rAAV2tYF-GRK1-hRPGRstb both corrected rod and cone opsin mislocalization, two early markers of disease in the XLPRA2 canine model of RPGR-XLRP. These results support the selection and use of rAAV2tYF-GRK1-hRPGRco (AGTC-501) and guided the initial doses in clinical studies in patients with XLRP caused by RPGR mutations.

[1]  A. Cideciyan,et al.  Toxicity and Efficacy Evaluation of an AAV Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa. , 2020, Human gene therapy.

[2]  Paul D. Gamlin,et al.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  R. MacLaren,et al.  Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  H. Khanna.  Photoreceptor Sensory Cilium: Traversing the Ciliary Gate , 2015, Cells.

[5]  W. Hauswirth,et al.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease , 2015, Proceedings of the National Academy of Sciences.

[6]  M. Sandberg,et al.  Photoreceptor Rescue by an Abbreviated Human RPGR Gene in a Murine Model of X-linked Retinitis Pigmentosa , 2015, Gene Therapy.

[7]  A. Wright,et al.  RPGR: Its role in photoreceptor physiology, human disease, and future therapies , 2015, Experimental eye research.

[8]  W. Hauswirth,et al.  Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis Pigmentosa. , 2015, Human gene therapy.

[9]  P. Sieving,et al.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. , 2015, Human molecular genetics.

[10]  Alexander Sumaroka,et al.  Canine Retina Has a Primate Fovea-Like Bouquet of Cone Photoreceptors Which Is Affected by Inherited Macular Degenerations , 2014, PloS one.

[11]  P. Melillo,et al.  Macular abnormalities in Italian patients with retinitis pigmentosa , 2014, British Journal of Ophthalmology.

[12]  A. Swaroop,et al.  Rd9 Is a Naturally Occurring Mouse Model of a Common Form of Retinitis Pigmentosa Caused by Mutations in RPGR-ORF15 , 2012, PloS one.

[13]  Hemant Khanna,et al.  Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa , 2012, Proceedings of the National Academy of Sciences.

[14]  T. Flotte,et al.  Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. , 2011, Human gene therapy.

[15]  W. Hauswirth,et al.  rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters , 2010, Gene Therapy.

[16]  G. Acland,et al.  Age-dependent disease expression determines remodeling of the retinal mosaic in carriers of RPGR exon ORF15 mutations. , 2009, Investigative ophthalmology & visual science.

[17]  G. Veres,et al.  Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. , 2009, Human gene therapy.

[18]  James M. Wilson,et al.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.

[19]  A. Wright,et al.  Focus on Molecules: RPGR. , 2007, Experimental eye research.

[20]  B. Rosner,et al.  Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. , 2007, Investigative ophthalmology & visual science.

[21]  G. Acland,et al.  A frameshift mutation in RPGR exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa. , 2006, Investigative ophthalmology & visual science.

[22]  G. Acland,et al.  Application of a New Subretinal Injection Device in the Dog , 2004, Cell transplantation.

[23]  G. Acland,et al.  Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. , 2002, Human molecular genetics.

[24]  C. Craft,et al.  Species-Specific Differences in Expression of G-Protein-Coupled Receptor Kinase (GRK) 7 and GRK1 in Mammalian Cone Photoreceptor Cells: Implications for Cone Cell Phototransduction , 2001, The Journal of Neuroscience.

[25]  A. Ciccodicola,et al.  Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa , 2000, Nature Genetics.

[26]  G. Fishman.  Retinitis Pigmentosa: Genetic Percentages , 1978 .

[27]  Allan Bird.  X-linked retinitis pigmentosa. , 1975, The British journal of ophthalmology.

[28]  W. Hauswirth,et al.  Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases. , 2016, Human gene therapy.

[29]  W. Hauswirth,et al.  Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. , 2016, Human gene therapy. Clinical development.